TRIPASS XR تري باس

7

7

p

h

a

r

ma

c

o

lo

g

ic

e

ffe

c

t

s

,

1

9

0

4–

1

9

0

5

r

e

p

la

c

e

me

nt

th

e

r

a

p

y

,

1

9

1

0

,

1

9

1

4

,

1

9

2

1

N

i

c

o

t

i

n

e

g

u

m

,

fo

r

s

m

o

k

i

n

g

c

e

s

s

a

t

i

o

n

,

1

9

1

1

–

1

9

1

3

t

a

dv

e

r

s

e

r

e

a

c

t

io

n

s

,

1

9

1

6

dis

a

dv

a

nt

a

g

e

s

o

f,

1

9

1

6

do

s

a

g

e

,

1

9

1

5

–

1

9

1

6

p

a

t

ie

nt

e

du

c

a

t

io

n

,

1

9

1

6

N

i

c

o

t

i

n

e

i

n

h

a

l

e

r

,

fo

r

s

m

o

k

i

n

g

c

e

s

s

a

t

i

o

n

,

1

9

1

1

–

1

9

1

3

t

,

1

9

1

8

–

1

9

1

9

N

i

c

o

t

i

n

e

l

o

z

e

n

g

e

,

fo

r

s

m

o

k

i

n

g

c

e

s

s

a

t

i

o

n

,

1

9

1

1

–

1

9

1

3

t

adverse reactions, 1916

disadvantages, 1916

dosage, 1916

patient education, 1916

Nicotine nasal spray, for smoking cessation, 1911–1913t

advantages, 1918

adverse reactions, 1918

dosage, 1918

patient education, 1918

Nicotine patch, for smoking cessation, 1911–1913t

adverse reactions, 1915

and dermatologic conditions, 1915

disadvantages of, 1915

dosage, 1915

patient education, 1915

Nifazodone, 120t

Nifedipine, 214, 339, 923, 985t, 993, 2261t

for Raynaud’s disease, 171

Nikkomycins, 1626

Nilotinib, 128, 470t, 1990, 2031

Nilutamide, for prostate cancer, 2093

Nipent (see Pentostatin)

Nipride (see Nitroprusside)

Nitazoxanide, 1706

for diarrhea by C. parvum, 1453

for giardiasis, 1704t

Nitrates, 214

for angina, 221

for cardiac syndrome X, 229

GERD and, 503t

for HF, 271

and hydralazine, 294

oral, 294

organic, 215t

Nitro-Bid IV (see Nitroglycerin)

Nitrofurantoin, 977, 1500

adverse effects of, 1494

for chronic antimicrobial therapy, 1499t

for cystitis, 1489

for UTI, 1489t

Nitroglycerin (NTG; Nitro-Bid IV; Nitro-Stat IV; Tridil), 335t, 2207t

for ACS, 242t

administration, 547

for chest pain, 340

CNS stimulants, 1883

for hypertensive emergencies, 343–344

for MI, 253

Nitroimidazoles, 1526

Nitropress (see Nitroprusside)

Nitroprusside (Nipride, Nitropress), 335–336t, 2207t

cyanide toxicity from, 341–342

doses of, 341

hemodynamic effects of, 341

for HTN and LV dysfunction, 297

for hypertensive emergency, 340–341

sodium, 341–342

thiocyanate toxicity from, 342

Nitro-Stat IV (see Nitroglycerin)

Nivolumab, 469t, 2066

Nizatidine, 977, 1216t, 2163t

H2RA, 483t, 484

NMDA (see N-methyl-D-aspartate (NMDA))

N-methyl-D-aspartate (NMDA), 1781, 1885

for Alzheimer’s disease, 2238

N,N-diethyl-m-toluamide (DEET), 1701

skin repellents (Repel Sportsmen), 1721

Non–angiotensin-converting enzyme inhibitor vasodilator therapy, 293–294

Non-aspirin NSAIDs, 491

Nondihydropyridines, 345, 605

Nonsteroidal antiinflammatory drugs (NSAIDs), 248, 460, 694, 1633, 1720, 2009

for acute gout, 909, 913

adverse effects, 1015–1016

and AIN, 645

common cold, 1661

contraindications, 1016

for critically ill patients, 1208

for drug-induced lupus, 692

for dysmenorrhea, 1014

effects on kidney, 890–891

for endometriosis, 1019

GERD and, 503t

and GI bleeding, 887

induced anaphylaxis, 694

for JIA, 901, 902, 904

and methotrexate, 892–893

for migraine headache, 1240, 1242

for OA, 867, 870–872, 870t, 871f

for PMS, 1025

for postoperative pain management, 1180

for psoriasis, 834, 842

for RA, 881–882, 887–891

and sodium content, 275

for systemic lupus erythematosus, 706–707, 712t, 713t

for tension-type headache, 1245

teratogenic effects, 973t

ulcers from, 489, 489t, 490–491, 490t

Norcuron (see Vecuronium)

Norepinephrine (NE), 265, 689t, 1733, 2207t, 2208

for cardiogenic shock, 365

for postoperative cardiac failure, 363t

for SBP, 363–364

for septic shock, 370–371

Norethindrone, 936–938t, 1021–1022

Norethindrone acetate, 1033t

Norfloxacin (Noroxin), 549, 1326t

for chronic antimicrobial therapy, 1499t

for UTI, 1489t

Norgestimate, 936–937t

Norgestrel, 936–937t

Normodyne (see Labetalol)

Noroxin (see Norfloxacin)

Nortriptyline, 1181t, 1187t, 1191 (see also Antidepressants)

for depressive disorders, 1819t, 1821t

Novamine, 794t

Novantrone (see Mitoxantrone)

Novolin N, 1087

NovoLog (see Insulin aspart)

NPH (see Neutral protamine Hagedorn (NPH))

NSAIDS (see Nonsteroidal antiinflammatory drugs (NSAIDs))

NTG (see Nitroglycerin (NTG))

Nystatin, 1624, 1624t, 1626t, 1634

p. 2309

p. 2310

O

Obinutuzumab, 469t

Ocrelizumab, 1223

Octinoxate, 849t, 852

Octisalate (octyl salicylate), 849t, 852

Octocrylene, 849t, 852

Octreotide, 502, 549, 803

administration, 555

for variceal bleeding, 513

Ocular therapies, for rhinitis, 438

Ocupress (see Carteolol)

Ofatumumab, 469t

Ofloxacin (Floxin), 942t, 1326t

Olanzapine (Zyprexa), 472t, 474t, 475–476, 1267, 1739, 1797t, 1799t, 1837, 1849t

for acute agitation, 1846

for acute mania, 1844–1845, 1845t

for anticholinergic, 1801

for BD, 1997t

for bipolar disorder, 1849t

for CINV, 473

drug interaction with smoking, 1906t

for dyslipidemia, 1804

for end-of-life care, 88

for FGAs, 1803

for hyperprolactinemia, 1803

for OCD, 1757

for schizophrenia, 1788, 1791t, 1792, 1793, 1793t

Olanzapine–fluoxetine, 1997t

for bipolar depression, 1847t, 1849t

Olanzapine pamoate, 1795t

Olaparib, 470t

Olmesartan, 127, 154t

Olodaterol, 420t, 421, 422

Olopatadine, 439t, 440t, 1165

for allergic rhinitis, 432

Olsalazine (Dipentum), 523t

for inflammatory bowel disease, 521t

Omacetaxine, 469t

Omalizumab (Xolair)

for allergic rhinitis, 435

for asthma, 400

side effects of, 400

Ombitasvir, 1688

Omega-3 fatty acids

adverse effects, 126

for ASD, 1856

clinical pearls, 126

drug interactions, 126

for dysmenorrhea, 1015

efficacy, 126

mechanism of action, 125

pharmacokinetics/pharmacodynamics, 126

place in therapy, 126

Omeprazole, 228, 483t, 1216t, 2163t

PPI, 484, 485

for preventing SRMB, 515t

Omnaris (see Ciclesonide)

Omnicef (see Cefdinir)

Omnipen (see Ampicillin)

Omtryg, 126

Ondansetron

for NVP, 975, 976, 976t

for PONV, 478t

Ondansetron (Zofran), 472t

for NVP, 975, 976, 976t

ODT, for nausea and vomiting, 91–92

for PONV, 478t

Ophthalmic therapies, for allergic rhinitis, 434

Opiates, for osteoarthritis, 2228

Opioids, 1182t, 1196t

associated with hepatic encephalopathy, 552

for breakthrough pain management, 1201

chronic, assessment of, 1196

in critically ill patients, 1211, 1212t

discontinuing, 1196–1197

for neuropathic pain, 1188

for OA, 872

risk addiction of, 1195–1196, 1195t

risk management of, 1194

side effect management, 1203, 1203t

Oprelvekin, 1972

Optipranolol (see Metipranolol)

Optivar (see Azelastine)

OPV (see Oral polio vaccine (OPV))

Oralair, for allergic rhinitis, 435t

Oral analgesics, for burn injuries, 863

Oral anticoagulation, 195t

Oral azithromycin, 463

Oral bisphosphonates, 454

Oral contraceptives

for IVF, 961–962

for migraine headache, 1237

Oral corticosteroids, 526

Oral electrolyte solutions, 2161t

Oral fluoroquinolones, 464

Oral iron preparations, 613t

Oral norfloxacin, 549

Oral polio vaccine (OPV), 1358

Orbactiv (see Oritavancin)

Oritavancin (Orbactiv)

adverse effects of, 1333t

for aerobic gram-positive cocci, 1326t

Orlistat (Xenical, Alli), 762–763

Orphenadrine citrate, 1186t

Ortho Tri-Cyclen, 829, 830, 1923

Oseltamivir (Tamiflu), 1649t

adverse effects of, 1647t

for influenza, 1415t, 1656

pharmacokinetics of, 1653t

Osmotic diuretics, 581

Ospemifene (Osphena), 1037

Osphena (see Ospemifene)

OTC products (see Over-the-counter (OTC) products)

Over-the-counter (OTC) products, 40

antisecretory drugs, 488

Oxacillin (see Nafcillin)

Oxaliplatin, 469t, 1978–1979t, 1981t, 1996

for adverse effects, 2076–2077, 2080

for colon cancer, 2073

neurotoxicity of, 1986–1987

peripheral nerve toxicity of, 1986–1987

and peripheral neuropathies, 1986–1987

Oxaprozin, 888t

Oxazepam, 1737t, 1746

Oxazolidinone, 1399

Oxcarbazepine, 942t, 1181t, 1187t, 1279t, 1281

for acute mania, 1845

for diabetes, 1145

for seizures, 1285t, 1286

Oxiconazole, 1624t

Oxybenzone, 849t, 852

Oxybutynin chloride, 2251

Oxycodone, 499, 1187t

dosage of, 1199t

Oxygen therapy, 689t, 1244, 1659

Oxymetazoline (Afrin), 434t

Oxyquinolines, 1626

Oxytocin, 988–989

administration of, 990

adverse effects, 990–991

dosage, 990

and lactation, 999

mechanism of action, 990

for postpartum hemorrhage, 997, 997t

and uterine activity, 990

P

PAAFs (see Pediatric amino acid formulations (PAAFs))

PABA (see Para-aminobenzoic acid (PABA))

P

a

c

l

i

t

a

x

e

l

(

T

a

x

o

l

)

,

2

2

6

,

4

6

9

t

,

9

4

2

t

,

1

9

7

8

–

1

9

7

9

t

,

1

9

8

1

t

,

1

9

8

2

t

,

1

9

8

7

,

1

9

9

0

fo

r

b

r

e

a

s

t

c

a

n

c

e

r

,

2

0

5

3

n

e

ur

o

t

o

x

ic

ity

o

f,

1

9

8

5

t

fo

r

N

S

C

L

C

,

2

0

6

2

t

,

2

0

6

3

t

,

2

0

6

4

t

p

e

r

ip

h

e

r

a

l

n

e

r

v

e

t

o

x

ic

ity

o

f,

1

9

8

6

P

a

d

i

m

a

t

e

O

,

8

4

9

t

,

8

5

2

P

a

l

b

o

c

i

c

l

i

b

,

4

7

0

t

P

a

l

i

fe

r

m

i

n

,

1

9

7

5

P

a

l

i

p

e

ri

d

o

n

e

(

I

n

v

e

g

a)

,

1

7

9

6

t

,

1

7

9

7

t

,

1

7

9

9

t

fo

r

hyp

e

rp

r

o

la

c

t

in

e

mia

,

1

8

0

3

fo

r

s

c

h

iz

op

hr

e

nia

,

1

7

8

8

,

1

7

9

1

t

P

a

l

i

v

i

z

u

m

a

b

a

dminis

tr

a

t

io

n

o

f,

1

6

5

8

do

s

a

g

e

o

f,

1

6

5

8

a

g

a

in

s

t

R

S

V

,

1

6

5

8

P

a

l

o

n

o

s

e

t

r

o

n

(

A

l

o

x

i

,

A

k

y

n

z

e

o

)

,

4

7

2

t

,

4

7

3

,

4

7

5

–

4

7

6

fo

r

P

O

N

V

,

4

7

8

t

P

a

m

a

b

r

o

m

,

1

0

1

5

P

a

m

i

d

r

o

n

a

t

e

,

5

8

9

t

,

5

9

0

,

2

0

3

8

,

2

2

7

7

,

2

2

7

8

P

-

a

m

i

n

o

s

a

l

i

c

yl

i

c

a

c

i

d

(

P

A

S

)

,

1

4

3

0

t

P

a

n

i

t

u

m

u

m

a

b

,

4

6

9

t

fo

r

c

o

lo

n

c

a

n

c

e

r

,

2

0

7

3

P

a

n

o

b

i

n

o

s

t

a

t

,

4

7

0

t

P

a

n

t

o

p

r

az

o

l

e

,

4

8

3

t

,

4

8

4

,

4

8

5

,

5

0

2

,

1

2

1

6

t

,

2

1

6

3

t

fo

r

p

r

e

v

e

nt

in

g

S

R

M

B

,

5

1

5

t

P

a

p

av

e

ri

n

e

,

2

2

6

6

P

a

r

a

-

a

m

i

n

o

b

e

n

z

o

i

c

a

c

i

d

(

P

A

B

A

)

,

8

4

9

,

8

4

9

t

P

a

r

a

b

e

n

,

8

2

2

t

P

a

r

a

c

e

t

a

m

o

l

(

s

e

e

A

c

e

t

a

m

i

n

o

p

h

e

n

)

P

a

r

a

p

h

e

n

yl

e

n

e

d

i

a

m

i

n

e

,

8

2

2

t

P

a

r

a

p

l

a

t

i

n

(

s

e

e

C

a

rb

o

p

l

a

t

i

n

)

P

a

ri

c

a

l

c

i

t

o

l

,

6

2

2

P

a

ri

t

a

p

r

e

v

i

r

,

1

6

8

8

P

a

rl

o

d

e

l

(

s

e

e

B

r

o

m

o

c

ri

p

t

i

n

e

)

P

a

r

o

m

o

m

y

c

i

n

p. 2

3

1

0

p. 2

3

1

1

fo

r

a

me

b

ic

id

e

s

,

1

7

0

3

t

fo

r

a

me

b

ic

liv

e

r

a

b

s

c

e

s

s

,

1

7

0

4

t

fo

r

g

ia

r

dia

s

is

,

1

7

0

4

t

P

a

r

o

x

e

t

i

n

e

(

P

a

x

i

l

)

,

5

9

,

1

0

2

7

t

,

1

7

3

8

t

,

1

7

4

8

,

1

8

1

0

fo